Search Results
Your search for ,ITS matches 8694 pages
Showing 2351 - 2400AACR and The Mark Foundation for Cancer Research Announce New Grants
The American Association for Cancer Research (AACR) and The Mark Foundation for Cancer Research recently announced five grants to support innovative research focused on understanding the influence of a patient’s biology on the genesis, development, treatment, and survivorship of cancer. Each...
Kathy Giusti, MBA; Nancy Pelosi; and Charles L. Sawyers, MD, FAACR, to Receive AACR Distinguished Public Service Awards
The American Association for Cancer Research (AACR) will present Distinguished Public Service Awards to three individuals whose extraordinary work has exemplified the AACR’s mission to prevent and cure all cancers through research, education, communication, collaboration, science policy, advocacy,...
How Interested Are Patients in Integrative Therapies, and How Much Are They Willing to Pay for Them?
The top two barriers to accessing complementary and integrative therapies, according to a survey of 576 patients with cancer and caregivers, were cost, cited by 56%, and a lack of knowledge about the therapies, cited by 52.1%. “Other barriers included a lack of time (29.2%), location of the...
Grateful to Be Alive
Everything about my breast cancer diagnosis, from my presentation to diagnosis, was strange. In the spring of 2006, I was performing my monthly breast self-exam when I felt a hard lump in the upper left quadrant of my left breast. Having lost a good friend to breast cancer 4 years earlier, I was...
Cancer Care in Sudan During the COVID-19 Pandemic
Sudan is one of Africa’s largest countries, rich in underutilized natural resources but rife with conflicts and civil wars that have been ongoing since it gained its independence in 1956. These problems have reflected negatively on the health-care system. Khartoum, the capital of Sudan, is a busy...
Anti-BCMA–Directed CAR T-Cell Gene Therapy in Relapsed or Refractory Myeloma
"The noblest pleasure is the joy of understanding.” —Leonardo da Vinci To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel...
A Physician-Scientist’s Mother, Who Nursed Those With Chronic Diseases, Fueled His Passion for Biomedical Research
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Griffin P. Rodgers, MD, MACP, Director of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH). Dr. Rodgers, a physician-scientist,...
Cemiplimab-rwlc for Locally Advanced and Metastatic Basal Cell Carcinoma
On February 9, 2021, cemiplimab-rwlc was granted regular approval for the treatment of patients with locally advanced basal cell carcinoma (BCC) who were previously treated with a Hedgehog pathway inhibitor or for whom this type of therapy is not appropriate and granted accelerated approval for...
CancerCare® Appoints Mark D. Peters II, PharmD, as Vice President for New Business Development and Outreach
CancerCare, the leading national nonprofit organization providing free support services to anyone affected by cancer, recently welcomed Mark D. Peters II, PharmD, to its team as Vice President for New Business Development and Outreach. Dr. Peters, who has more than 30 years of clinical and...
‘Dangling’ Accelerated Approvals of Anti–PD-1/PD-L1 Antibodies to Be Discussed at FDA Oncologic Drugs Advisory Committee Meeting
In a Perspective article in The New England Journal of Medicine, Julia A. Beaver, MD, and Richard Pazdur, MD, of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCD), discussed issues surrounding “dangling” accelerated approvals of anti–PD-1/PD-L1 antibodies—ie,...
Improvement Programs to Optimize Patient Care for Black Americans With Breast Cancer
Eight oncology practices in eight different U.S. metropolitan areas with high rates of breast cancer disparities between Black and White Americans have been selected to participate in ASCO’s quality programs, including the Quality Oncology Practice Initiative (QOPI®)and Quality Training Program...
New ASCO Guideline Offers Recommendations for Neoadjuvant Breast Cancer Treatment
ASCO has released a new guideline regarding the use of neoadjuvant chemotherapy, endocrine therapy, and targeted therapy in breast cancer.1 “This is the first time ASCO has embarked on a guideline for neoadjuvant therapy,” said Larissa A. Korde, MD, of the National Cancer Institute, and guideline...
Expert Point of View: Lisa Baumann Kreuziger, MD, MS
Lisa Baumann Kreuziger, MD, MS, Associate Professor of Hematology/Oncology at Versiti/Medical College of Wisconsin, Milwaukee, introduced Terry B. Gernsheimer, MD, at the Plenary Session and spoke with The ASCO Post about the results of the study. “The investigators of the A-TREAT trial tested a...
Study Finds Tranexamic Acid Unable to Prevent Bleeding in Patients With Hematologic Malignancies
In the first randomized trial to evaluate prophylactic antifibrinolytic therapy in patients with hematologic malignancies, tranexamic acid failed to reduce bleeding or the need for transfusion vs placebo. The study was featured as a Plenary Session during the 2020 American Society of Hematology...
MANIFEST-2: CPI-0610 Shows Benefit in Myelofibrosis
The novel targeted agent CPI-0610 enhanced responses to ruxolitinib in patients with myelofibrosis enrolled in the global phase II MANIFEST-2 trial, investigators reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1,2 “Preliminary data demonstrate the...
Adult Survivors of AYA Cancers May Be More Likely to Experience Medical Financial Hardship
A new study has found higher rates of medical financial hardship among adult survivors of adolescent and young adult (AYA) cancers than in adults without a history of cancer in the United States. The research was published by Lu et al in JNCI: The Journal of the National Cancer Institute....
Certain Genetic Mutations May Increase Risk of Death From Infection in Patients With CLL
Death from infection—the leading cause of death for patients with chronic lymphocytic leukemia (CLL)—may be linked to specific gene mutations, according to results from a study published by Else et al in the journal Leukemia. Testing for these mutations could be used to identify patients at a...
Squamous Cell Carcinoma of the Head and Neck: Current Status and Future Directions
Although head and neck cancers include multiple histologies and primary sites, squamous cell carcinomas (SCC) originating in the oropharynx, oral cavity, larynx, or hypopharynx are the most common. Today, we recognize different types of head and neck cancers, primarily those that are human...
Patrizia Cavazzoni, MD, Named Director of the FDA’s Center for Drug Evaluation and Research
On April 12, Patrizia Cavazzoni, MD, was announced as the Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA). Janet Woodcock, MD, Acting Commissioner of the FDA, noted on Twitter: “Pleased to announce the permanent appointment of Patrizia ...
Estimated Shifts in Cancer Incidence and Death Over Next 2 Decades
In the next 2 decades, rankings of incidence and death across cancer types in the United States will undergo important changes, according to new research published by Lola Rahib, PhD, and colleagues in JAMA Network Open. The study estimates that pancreatic cancer is on course to become the...
Tumor Mutational Burden as Predictor of Immune Response: Variance Between Female and Male Patients With Melanoma
Tumor mutational burden (TMB) was an accurate predictor of response to treatment with immune checkpoint inhibitors for female patients with melanoma, but not for male patients, according to results of a study presented by Sinha et al during the virtual American Association for Cancer Research...
Liquid Biopsy Plus MRI for Predicting Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
Cirmena et al discussed whether using a liquid biopsy test to assess plasma cell-free DNA (cfDNA) integrity could improve the accuracy of magnetic resonance imaging (MRI) for predicting the achievement of complete response among patients with locally advanced breast cancer who had received...
Patients of Different Races With Early-Onset Colorectal Cancer Exhibit Distinct Genetic Features
Racial differences in genetic mutations were observed among patients with early-onset colorectal cancer, according to data presented by Andreana N. Holowatyj, PhD, MS, during the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 (Abstract 101). The incidence of early-onset ...
American Cancer Society Names Karen E. Knudsen, MBA, PhD, as Its Next Chief Executive Officer
Karen E. Knudsen, MBA, PhD, will be the next Chief Executive Officer of the American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN), starting June 1, 2021. She will take the reins from the retiring Gary Reedy, who has served as both...
Tebentafusp: First Treatment to Improve Overall Survival in Metastatic Uveal Melanoma
Treatment with tebentafusp, a novel bispecific fusion protein, reduced the risk of death from metastatic uveal melanoma at 14 months by half, compared with available treatments, in a phase III study presented by Piperno-Neumann et al at the virtual American Association for Cancer Research (AACR)...
Expert Point of View: David A. Braun, MD, PhD
Invited discussant David A. Braun, MD, PhD, of Dana-Farber Cancer Institute, Boston, said there are a couple of established pillars of systemic therapy for metastatic renal cell carcinoma (RCC). “An immune checkpoint inhibitor is a strong pillar, a [vascular endothelial growth factor tyrosine...
Belzutifan Shows Activity in Advanced Renal Cell Carcinoma, Both as a Single Agent and in Combination Therapy
Separate studies presented at the 2021 Genitourinary Cancers Symposium provide supportive evidence for belzutifan (formerly MK-6482) as an active treatment for metastatic clear cell renal cell carcinoma (RCC). One study showed single-agent activity for this novel approach in an early-phase trial,...
Cancer and COVID-19: Reflections at 1 Year
We who live and work in Seattle recently took note of two milestones: the first death of a patient from COVID-19 reported in the United States in Seattle on February 28, 2020, and recognition of 5,000 deaths from COVID-19 in the state of Washington on March 2, 2021. The juxtaposition of these two...
Novel Insights in Myelodysplastic Syndromes: Highlights From 2020 ASH Meeting
To complement The ASCO Post’s comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel clinical trial findings in myelodysplastic syndromes (MDS). For full details of...
Jeff Walker, MBA, Returns to Roswell Park in Newly Created Executive Role
An experienced executive has rejoined the Roswell Park Comprehensive Cancer Center team, announced Roswell Park President and Chief Executive Officer Candace S. Johnson, PhD. Jeff Walker, MBA, has been recruited back to Western New York to fill the new role of Executive Vice President of Operations ...
Leslie R. Boyd, MD, Appointed Director of Gynecologic Oncology at Perlmutter Cancer Center
Surgeon and women’s cancers expert Leslie R. Boyd, MD, has been named Director of the Division of Gynecologic Oncology at the Laura and Isaac Perlmutter Cancer Center and within the Department of Obstetrics and Gynecology at New York University (NYU) Langone Health. Dr. Boyd joined NYU Langone in...
Johan Vansteenkiste, MD, PhD, and Fiona Blackhall, PhD, FRCP, Honored for Lung Cancer Research by ESMO and IASLC
The European Society for Medical Oncology and the International Association for the Study of Lung Cancer recently presented the Heine H. Hansen Award 2021 to Johan Vansteenkiste, MD, PhD, Professor of Medicine at the Catholic University of Leuven and Head of Clinic in the Respiratory Oncology Unit...
Expert Point of View: Gillianne G.Y. Lai, MBBS
Gillianne G.Y. Lai, MBBS, of the National Cancer Centre, Singapore, discussed the presentations on novel agents for exon 20 insertion mutations in non–small cell lung cancer (NSCLC), which account for about one-third of tyrosine kinase resistance mutations. Although tyrosine kinase mutations are...
Novel Decision-Making Tool for Androgen-Deprivation Therapy for Patients With Prostate Cancer
According to a retrospective study, the combined clinical and cell-cycle risk (CCR) score may be able to accurately predict which patients with intermediate- and high-risk prostate cancer will have little additional benefit from androgen-deprivation therapy added to dose-escalated radiotherapy and...
Ze’ev Ronai, PhD, Named Director of Sanford Burnham Prebys Cancer Center
Sanford Burnham Prebys Medical Discovery Institute has appointed cancer researcher Ze’ev Ronai, PhD, as Director of its National Cancer Institute (NCI)-designated Cancer Center. Established in 1976, the Cancer Center is one of only seven NCI-designated Basic Laboratory Cancer Centers in the...
City of Hope Announces New Radiation Oncology Chair
City of Hope recently announced the appointment of Terence M. Williams, MD, PhD, as Professor and Chair of its Department of Radiation Oncology. Dr. Williams takes the helm of one of the largest and most experienced radiation oncology services in the country, with more than 15 locations and 42...
Yoga in Oncologic Care: An Evidence-Based Treatment to Improve Outcomes
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Increasingly, patients with cancer desire nonpharmacologic strategies for managing their...
How Exceptional Responders Are Providing Clues to Personalizing Cancer Treatment
The findings from a recent study of patients with cancer who had an exceptional response to chemotherapy are yielding new clues on the molecular changes in patients’ tumors. These findings may explain the genetic alterations contributing to these patients’ dramatic and long-lasting responses to...
Cardiovascular Disease in Hematologic Malignancies: Who Is at Risk?
Given the improvements in diagnostic strategies, treatment, and supportive care, long-term survival is now an expected outcome for a large majority of patients with hematologic malignancies. Unfortunately, radiation therapy and anthracyclines, which form the backbone of front-line treatment, have...
Risk of Leukemia in Pediatric Patients With Down Syndrome
In a recent study reported by Marlow et al in The Journal of Pediatrics, researchers assessed the risk of leukemia in children with Down syndrome. Their findings pointed to stronger-than-expected associations between Down syndrome and acute myeloid leukemia (AML). Down syndrome is one of the most...
Role of Antibody-Drug Conjugates Across Breast Cancer Subtypes
For the treatment of breast cancer, antibody-drug conjugates are emerging as effective players that could impact all subtypes of this disease, according to Kevin Kalinsky, MD, MS, Director of the Glenn Family Breast Cancer at the Winship Cancer Institute of Emory University, Atlanta. In the...
Diet and Exercise Intervention May Increase Efficacy of Chemotherapy in Pediatric Patients With Leukemia
Research published by Orgel et al in the journal Blood Advances showed that restricting calories, reducing fat and sugar intake, and increasing physical activity may boost the effectiveness of chemotherapy for older children and adolescents with leukemia. This intervention, which improved...
President Biden Issues Proclamation on National Cancer Control Month 2021
On March 31, President Joseph R. Biden, Jr, issued the following statement on National Cancer Control Month. Despite the incredible advancements we have made in recent years, cancer remains the second-leading cause of death in the United States. Behind this statistic are millions of Americans who...
Lymph Node Collection Kit May Help Improve Outcomes After Lung Cancer Surgery
A lymph node collection kit may help surgeons attain complete resection and improve long-term survival after curative-intent lung cancer surgery, according to a recent study published by Matthew Smeltzer, PhD, and colleagues in JTO Clinical and Research Reports. Surgical resection is the most...
Does Adding Adjuvant Concurrent Trastuzumab to Radiotherapy After Lumpectomy for HER2-Positive DCIS Reduce Ipsilateral Recurrence?
As reported in the Journal of Clinical Oncology by Cobleigh et al, the phase III NRG Oncology/NSABP B-43 trial did not show a significant reduction in ipsilateral breast tumor recurrence with the addition of adjuvant concurrent trastuzumab to radiotherapy in women undergoing lumpectomy for...
Electroacupuncture and Auricular Acupuncture vs Usual Care for Chronic Musculoskeletal Pain in Cancer Survivors
In the PEACE study, reported in JAMA Oncology, Jun J. Mao, MD, MSCE, and colleagues found that both electroacupuncture and auricular acupuncture significantly reduced pain severity vs usual care in cancer survivors with chronic musculoskeletal pain. Noninferiority of auricular acupuncture to...
Does Consumption of Ultra-Processed Food and Drink Increase Colorectal Cancer Risk?
Consumption of ultra-processed food and drink could increase the risk of developing colorectal cancer. This was the conclusion of a large study published by Romaguera et al in Clinical Nutrition based on questionnaires about food behaviors completed by around 8,000 people in Spain. The study, the...
Expert Point of View: Rutika Mehta, MD, MPH
The FIGHT study’s invited discussant, Rutika Mehta, MD, MPH, a gastrointestinal oncologist at Moffitt Cancer Center, Tampa, Florida, noted the emergence of new biomarkers and their targeted agents in HER2-negative gastric or gastroesophageal junction cancer. Two important ones are FGFR2b—now...
Nivolumab Plus Chemotherapy: New Standard of Care in Advanced Gastric Cancer?
As first-line treatment for advanced gastric cancer, nivolumab plus chemotherapy leads to significantly improved progression-free and overall survival over chemotherapy alone, investigators reported during a Presidential Symposium of the European Society for Medical Oncology (ESMO) Virtual Congress ...
An Integrated Framework for Improving Outcomes in Pancreatic Cancer
Drawing on several lines of ongoing research, David A. Tuveson, MD, PhD, has created a theoretical framework to consider while developing clinical trials in pancreatic cancer. In his keynote lecture at the 2020 American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer, ...
